[{"id":"a68faa2b-d426-44af-a80f-b0fc99a1c7cd","acronym":"NXP800-101","url":"https://clinicaltrials.gov/study/NCT05226507","created_at":"2023-04-14T16:03:28.481Z","updated_at":"2025-02-25T15:12:35.833Z","phase":"Phase 1","brief_title":"A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer","source_id_and_acronym":"NCT05226507 - NXP800-101","lead_sponsor":"Nuvectis Pharma, Inc.","biomarkers":" ARID1A • BRCA","pipe":" | ","alterations":" ARID1A mutation • BRCA mutation","tags":["ARID1A • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NXP800"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-13"}]